Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquired |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:ceo |
gptkb:Tony_Coles
|
| gptkbp:clinical_trial |
Phase 3 trials
publicly traded Phase 2 trials |
| gptkbp:collaborates_with |
academic institutions
|
| gptkbp:develops |
therapeutics for Parkinson's disease
therapeutics for schizophrenia therapeutics for epilepsy |
| gptkbp:employees |
over 100
|
| gptkbp:focuses_on |
drug discovery
central nervous system disorders clinical development |
| gptkbp:founded |
gptkb:2018
|
| gptkbp:funding |
over $300 million
|
| gptkbp:has_partnerships_with |
biopharmaceutical companies
|
| gptkbp:has_pipeline |
clinical trials
|
| gptkbp:has_research_focus |
patient education
biomarkers stakeholder engagement clinical studies preclinical studies clinical outcomes regulatory submissions health economics disease mechanisms real-world evidence market access strategies clinical pathways treatment guidelines patient engagement strategies healthcare provider education commercialization strategies therapeutic candidates safety profiles investigational drugs patient populations clinical endpoints drug mechanisms efficacy profiles |
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cerevel Therapeutics
|
| gptkbp:investment |
gptkb:Sofinnova_Partners
gptkb:Foresite_Capital gptkb:Canaan_Partners gptkb:Bain_Capital_Life_Sciences gptkb:Orbi_Med_Advisors |
| gptkbp:lead_candidate |
CVL-751
CVL-865 CVL-936 |
| gptkbp:partnership |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:research_areas |
neurology
psychiatry |
| gptkbp:research_focus |
neuropsychiatric diseases
|
| gptkbp:stock_symbol |
CERE
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.cerevel.com
|
| gptkbp:bfsParent |
gptkb:Humana_Inc.
|
| gptkbp:bfsLayer |
6
|